Corrections

Conflicts of interest and pandemic flu

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3578 (Published 06 July 2010) Cite this as: BMJ 2010;341:c3578

Fiona Godlee, author of this editorial (BMJ 2010;340:c2947, doi:10.1136/bmj.c2947), has acknowledged an error: “I quoted a figure of $7-10bn as the industry’s profit from the sale of pandemic flu vaccines. This figure is incorrect. It was taken from a Council of Europe report,1 which quoted incorrectly from a report by investment bank JP Morgan. The actual figure in the JP Morgan report2 referred to estimated total sales (not profit) for pandemic vaccine and adjuvant, and was $6.9bn. Industry’s audited accounts for 2009 give sales figures for pandemic vaccine in 2009 in the region of $2.5bn. Industry analysts I have spoken to suggest that the total sales of pandemic flu vaccines from late 2008 through to early 2010 are likely to be double this at around $5bn. Again this figure is an estimate for sales revenue not profit.”

Notes

Cite this as: BMJ 2010;341:c3578

References

View Abstract